Verelan Pm

Cluster Headache, prophylaxis of Cluster headaches, Angina, Unstable + 7 more
Treatment
3 FDA approvals
20 Active Studies for Verelan Pm

What is Verelan Pm

VerapamilThe Generic name of this drug
Treatment SummaryVerapamil is a type of medication used to treat high blood pressure, irregular heartbeats, and chest pain. It was the first medication of its kind to be introduced in the 1960s and belongs to a group of medications called calcium channel blockers, which includes drugs like diltiazem and flunarizine. Verapamil comes in two forms: the S-enantiomer and the R-enantiomer, with the S-enantiomer being more powerful but also metabolized faster.
Calanis the brand name
Verelan Pm Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Calan
Verapamil
1984
357

Approved as Treatment by the FDA

Verapamil, also called Calan, is approved by the FDA for 3 uses which include Hypertensive disease and Atrial Fibrillation or Flutter .
Hypertensive disease
Used to treat High Blood Pressure (Hypertension) in combination with Trandolapril
Atrial Fibrillation or Flutter
Used to treat Atrial Fibrillation or Flutter in combination with Digitoxin
Heart Rate
Used to treat Heart Rate in combination with Digitoxin

Effectiveness

How Verelan Pm Affects PatientsVerapamil is a drug used to treat heart rhythm problems, chest pain, and high blood pressure. It blocks a certain type of calcium channel in the body, which helps to regulate these conditions. Immediate-release versions must be taken 3 or 4 times a day, but there are extended-release forms that can be taken once a day. Those with severe heart problems should not take verapamil, as it can make these conditions worse.
How Verelan Pm works in the bodyVerapamil works by blocking L-type calcium channels. These channels are found in the muscle tissue that makes up the heart and blood vessels, and they help control how much calcium flows into the cells. By blocking these channels, verapamil reduces the amount of calcium that can enter the cells. This causes the blood vessels to relax, which lowers blood pressure and reduces the force the heart needs to pump blood. It also slows down electrical activity in the heart, which is helpful for people with arrhythmias. Verapamil may also affect other calcium channels, potassium channels, and adrenergic receptors to help treat cluster

When to interrupt dosage

The recommended dose of Verelan Pm is contingent upon the diagnosed affliction, including Tachycardia, Ventricular, Unstable Angina Pectoris and Vasospastic Angina. The amount of dosage depends on the method of delivery as depicted in the table below.
Condition
Dosage
Administration
Vasospastic Angina
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Angina, Stable
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Heart Rate
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
prophylaxis of Cluster headaches
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Angina, Unstable
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Cluster Headache
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Hypertensive disease
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Tachycardia, Ventricular
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Tachycardia, Supraventricular
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Atrial Fibrillation or Flutter
180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL
Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral

Warnings

Verelan Pm has eleven contraindications and should not be utilized in tandem with the conditions given in the following table.Verelan Pm Contraindications
Condition
Risk Level
Notes
Atrioventricular Block
Do Not Combine
Ventricular Tachycardia
Do Not Combine
Atrial Fibrillation
Do Not Combine
Shock, Cardiogenic
Do Not Combine
accessory bypass tract
Do Not Combine
Heart Failure
Do Not Combine
Pulse Frequency
Do Not Combine
Sick Sinus Syndrome
Do Not Combine
Bradycardia
Do Not Combine
Hypotension
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Verapamil may interact with Pulse Frequency
There are 20 known major drug interactions with Verelan Pm.
Common Verelan Pm Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Verapamil.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Verapamil.
Acepromazine
Major
Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Verapamil.
Alfuzosin
Major
Verapamil may increase the hypotensive activities of Alfuzosin.
Verelan Pm Toxicity & Overdose RiskThe lowest toxic dose of verapamil in women is 14.4mg/kg and in men is 3.429mg/kg. The toxic dose in rats is 150mg/kg and in mice is 163mg/kg. If someone has overdosed on verapamil, treatment is generally supportive. Symptoms of overdose may include low blood pressure, slow heart rate, irregular heartbeat or non-cardiogenic pulmonary edema. In acute cases, doctors may use gastrointestinal decontamination with cathartics or bowel irrigation. Patients with severe heart depression may require intravenous calcium, atropine, or other treatments. If
image of a doctor in a lab doing drug, clinical research

Verelan Pm Novel Uses: Which Conditions Have a Clinical Trial Featuring Verelan Pm?

34 active clinical trials are assessing the capability of Verelan PM in managing Chronic Stable Angina Pectoris, Tachycardia, Ventricular and Paroxysmal Supraventricular Tachycardia (PSVT).
Condition
Clinical Trials
Trial Phases
Cluster Headache
2 Actively Recruiting
Phase 1, Phase 2
Heart Rate
0 Actively Recruiting
Tachycardia, Supraventricular
2 Actively Recruiting
Phase 3, Phase 2
Angina, Unstable
2 Actively Recruiting
Not Applicable
prophylaxis of Cluster headaches
0 Actively Recruiting
Vasospastic Angina
1 Actively Recruiting
Phase 2, Phase 3
Angina, Stable
0 Actively Recruiting
Atrial Fibrillation or Flutter
0 Actively Recruiting
Tachycardia, Ventricular
0 Actively Recruiting
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3

Verelan Pm Reviews: What are patients saying about Verelan Pm?

5Patient Review
10/6/2007
Verelan Pm for High Blood Pressure
This drug has been effectively treating my hypertension in conjunction with Lisinopril. I have experienced no negative side effects from this medication to date. Because there is no generic for this prescription at the moment, it does come at a higher cost; however, for me, it has been worth every penny.
5Patient Review
4/5/2011
Verelan Pm for High Blood Pressure
I'm so glad my doctor added Veralan to my Lisinopril and Amlodipine regimen. Not only did it get rid of my daily headaches, but my blood pressure has also lowered significantly in just a couple of weeks. I wish I had known about this sooner!
5Patient Review
6/11/2009
Verelan Pm for High Blood Pressure
I've been taking this for ten years with no adverse effects. The only thing is that it's pretty drowsy, so make sure to take it at night.
5Patient Review
10/23/2007
Verelan Pm for High Blood Pressure
I was informed by my pharmacist that there is now a generic option for this medication.
5Patient Review
11/24/2008
Verelan Pm for Migraine Prevention
I've found that this treatment, in conjunction with Topamax, has reduced the frequency and intensity of my migraines significantly.
5Patient Review
9/20/2009
Verelan Pm for Prevention of Paroxysmal Supraventricular Tachycardia
I've been using this medication for a while now, and I haven't had any issues with tachycardia since.
2Patient Review
5/8/2009
Verelan Pm for Migraine Prevention
I have been on this medication for two months and have actually seen an increase in the frequency of my migraines.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about verelan pm

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is verelan used to treat?

"Verapamil is a drug used to lower high blood pressure in order to prevent strokes, heart attacks, and kidney problems. Verapamil works by relaxing blood vessels so that blood can flow more easily and belongs to a class of drugs known as calcium channel blockers."

Answered by AI

Is verelan a calcium channel blocker?

"Verelan's active ingredient is a calcium channel blocker, which lowers blood pressure by reducing the force of the heart's contractions and relaxing the arteries."

Answered by AI

What form is verelan?

"The drug Verelan is used to treat irregular heart rhythms and belongs to a class of drugs known as antidysrhythmics, calcium channel blockers, and non-dihydropyridine calcium channel blockers."

Answered by AI

Can I take verapamil at night?

"You should take verapamil at around the same time(s) every day. Some verapamil products should be taken in the morning, and others should be taken at bedtime."

Answered by AI

Clinical Trials for Verelan Pm

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Have you considered Verelan Pm clinical trials? We made a collection of clinical trials featuring Verelan Pm, we think they might fit your search criteria.Go to Trials
Image of Tampa General Hospital in Tampa, United States.

Fasting for Myocardial Infarction

18+
All Sexes
Tampa, FL
The goal of this clinical trial is to find out whether fasting is necessary before urgent inpatient cardiac catheterizations. For patients presenting with urgent heart-related pain or even mild heart attacks, researchers want to know whether eating and drinking before their procedure improves comfort without raising the risk of complications. The study will answer: * Does eating and drinking before the procedure improve patient comfort? * Does it increase the risk of adverse events like vomiting, aspiration (food or liquid entering the lungs), breathing problems, or death, etc? Participants will be randomly assigned to either: * A standard fasting group (no food for 6 hours, no clear liquids for 2 hours), or * A no-fasting group (able to eat and drink as usual). Patients will complete brief surveys before the procedure to assess comfort and satisfaction. Researchers will also review medical records weekly and 30 days later to monitor for safety outcomes.
Recruiting
Has No Placebo
Tampa General HospitalSamip Vasaiwala, MD
Have you considered Verelan Pm clinical trials? We made a collection of clinical trials featuring Verelan Pm, we think they might fit your search criteria.Go to Trials
Image of Wayne Health Mobile Units in Detroit, United States.

Text Message Reminders for High Blood Pressure

18+
All Sexes
Detroit, MI
This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland. The present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).
Recruiting
Has No Placebo
Wayne Health Mobile UnitsSteven J Korzeniewski, PhD
Image of University of Alberta in Edmonton, Canada.

Egg White Powder for High Blood Sugar and High Blood Pressure

18 - 70
All Sexes
Edmonton, Canada
Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure. Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).
Phase 1
Waitlist Available
University of AlbertaJianping Wu, PhD
Image of Northern Arizona University in Flagstaff, United States.

CardioCare Quest for High Blood Pressure

18+
All Sexes
Flagstaff, AZ
This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.
Recruiting
Has No Placebo
Northern Arizona University (+1 Sites)Tochukwu Ikwunne, PhD
Have you considered Verelan Pm clinical trials? We made a collection of clinical trials featuring Verelan Pm, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security